Zebularine regulates early stages of mESC differentiation: Effect on cardiac commitment

Cell Death and Disease

Volumn 4, Issue 4, 2013, Pages

  Horrillo, A ^a   Pezzolla, D ^a,b   Fraga, M F ^c   Aguilera, Y ^a   Salguero Aranda, C ^b,d   Tejedo, J R ^b,d   Martin, F ^b,d   Bedoya, F J ^b,d   Soria, B ^a,b   Hmadcha, A ^a,b  

^a CABIMER Andalusian Center for Molecular Biology and Regenerative Medicine CSIC University of Seville UPO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Department of Epigenetic   (Spain)

^d UNIVERSIDAD PABLO DE OLAVIDE   (Spain)

Author keywords

AzadC; Embryonic stem cells; Mesoderm; Methylation; Nitric oxide; Zebularine

Indexed keywords

BIOLOGICAL MARKER; BISULFITE; DILTIAZEM; ISOPRENALINE; ZEBULARINE; CYTIDINE; DRUG DERIVATIVE; PYRIMIDIN 2 ONE BETA RIBOFURANOSIDE; PYRIMIDIN-2-ONE BETA-RIBOFURANOSIDE; DNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR SYSTEM; CELL DIFFERENTIATION; CHEMICAL ANALYSIS; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; EMBRYOID BODY; EMBRYONIC STEM CELL; ENZYME ACTIVITY; EPIGENETICS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HEART MUSCLE CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MESODERM; METHYLATION; METHYLATION SPECIFIC POLYMERASE CHAIN REACTION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TWO DIMENSIONAL GEL ELECTROPHORESIS; VALIDATION PROCESS; ANIMAL; CELL LINE; CYTOLOGY; DNA METHYLATION; DRUG EFFECT; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; CARDIAC SPECIFIC GENE; CARDIOVASCULAR SYSTEM DEVELOPMENT; DEVELOPMENT; DNA SEQUENCE; GENE; GENE EXPRESSION; PROTEIN EXPRESSION;

ANIMALS; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL LINE; CYTIDINE; DNA METHYLATION; EMBRYOID BODIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MICE; MYOCYTES, CARDIAC; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84879715193     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.88     Document Type: Article

References (45)

1. Ruers T, Bleichrodt RP. Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer 2002; 38: 1023-1033
2. Hafstrom LR, Holmberg SB, Naredi PL, Lindner PG, Bengtsson A, Tidebrant G et al. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol 1994; 3: 103-108
3. Alexander HR Jr, Libutti SK, Pingpank JF, Bartlett DL, Helsabeck C, Beresneva T. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol 2005; 12: 138-144
4. Varghese S, Xu H, Bartlett D, Hughes M, Pingpank JF, Beresnev T et al. Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma. Ann Surg Oncol 2010; 17: 1870-1877
5. Zeh III HJ, Brown CK, Holtzman MP, Egorin MJ, Holleran JL, Potter DM et al. A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer. Ann Surg Oncol 2009; 16: 385-394
6. Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R et al. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: A phase I study. Clin Cancer Res 2009; 15: 5584-5590
7. Younes A, Vose JM, Zelenetz AD, Smith MR, Burris HA, Ansell SM et al. A phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer 2010; 103: 1783-1787
8. Trarbach T, Moehler M, Heinemann V, Kohne CH, Przyborek M, Schulz C et al. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-Inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 2010; 102: 506-512
9. Zhang L, Fang B. Mechanisms of resistance to TRAIL-Induced apoptosis in cancer. Cancer Gene Ther 2005; 12: 228-237
10. Krueger A, Baumann S, Krammer PH, Kirchhoff S. FLICE-Inhibitory proteins: Regulators of death receptor-mediated apoptosis. Mol Cell Biol 2001; 21: 8247-8254
11. Lavrik IN, Krammer PH. Regulation of CD95/Fas signaling at the DISC. Cell Death Differ 2012; 19: 36-41
12. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190-195
13. Wilson TR, McLaughlin KM, McEwan M, Sakai H, Rogers KM, Redmond KM et al. c-FLIP: A key regulator of colorectal cancer cell death. Cancer Res 2007; 67: 5754-5762
14. Ullenhag GJ, Mukherjee A, Watson NF, Al-Attar AH, Scholefield JH, Durrant LG. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin Cancer Res 2007; 13: 5070-5075
15. Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L et al. c-FLIP inhibits chemotherapy-Induced colorectal cancer cell death. Oncogene 2006; 25: 838-848
16. Yoo J, Kim HR, Lee YJ. Hyperthermia enhances tumour necrosis factor-related apoptosisinducing ligand (TRAIL)-Induced apoptosis in human cancer cells. Int J Hyperther 2006; 22: 713-728
17. Yoo J, Lee YJ. Effect of hyperthermia and chemotherapeutic agents on TRAIL-Induced cell death in human colon cancer cells. J Cell Biochem 2008; 103: 98-109
18. Song X, Kim HC, Kim SY, Basse P, Park BH, Lee BC et al. Hyperthermia-enhanced TRAIL-And mapatumumab-Induced apoptotic death is mediated through mitochondria in human colon cancer cells. J Cell Biochem 2012; 113: 1547-1558
19. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 2003; 426: 895-899
20. Scudiero I, Zotti T, Ferravante A, Vessichelli M, Reale C, Masone MC et al. Tumor necrosis factor (TNF) receptor-Associated factor 7 is required for TNF alpha-Induced Jun NH2-Terminal kinase activation and promotes cell death by regulating polyubiquitination and lysosomal degradation of c-FLIP protein. J Biol Chem 2012; 287: 6053-6061
21. Kim Y, Suh N, Sporn M, Reed JC. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-Induced apoptosis. J Biol Chem 2002; 277: 22320-22329
22. Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K et al. The E3 ubiquitin ligase itch couples JNK activation to TNF alpha-Induced cell death by inducing c-FLIP(L) turnover. Cell 2006; 124: 601-613
23. Abedini MR, Muller EJ, Brun J, Bergeron R, Gray DA, Tsang BK. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. Cancer Res 2008; 68: 4511-4517
24. Yang F, Tay KH, Dong L, Thorne RF, Jiang CC, Yang E et al. Cystatin B inhibition of TRAIL-Induced apoptosis is associated with the protection of FLIP(L) from degradation by the E3 ligase itch in human melanoma cells. Cell Death Differ 2010; 17: 1354-1367
25. Wang L, Azad N, Kongkaneramit L, Chen F, Lu Y, Jiang BH et al. The Fas death signaling pathway connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation. J Immunol 2008; 180: 3072-3080
26. Stagni V, di Bari MG, Cursi S, Condo I, Cencioni MT, Testi R et al. ATM kinase activity modulates Fas sensitivity through the regulation of FLIP in lymphoid cells. Blood 2008; 111: 829-837
27. Stagni V, Mingardi M, Santini S, Giaccari D, Barila D. ATM kinase activity modulates cFLIP protein levels: Potential interplay between DNA damage signalling and TRAIL-Induced apoptosis. Carcinogenesis 2010; 31: 1956-1963
28. Yoo J, Lee YJ. Effect of hyperthermia on TRAIL-Induced apoptotic death in human colon cancer cells: Development of a novel strategy for regional therapy. J Cell Biochem 2007; 101: 619-630
29. Alcala MA Jr., Park K, Yoo J, Lee DH, Park BH, Lee BC et al. Effect of hyperthermia in combination with TRAIL on the JNK-Bim signal transduction pathway and growth of xenograft tumors. J Cell Biochem 2010; 110: 1073-1081
30. Krueger A, Schmitz I, Baumann S, Krammer PH, Kirchhoff S. Cellular FLICE-Inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 deathinducing signaling complex. J Biol Chem 2001; 276: 20633-20640
31. Yu JW, Shi Y. FLIP and the death effector domain family. Oncogene 2008; 27: 6216-6227
32. Chang DW, Xing Z, Pan Y, Algeciras-Schimnich A, Barnhart BC, Yaish-Ohad S et al. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J 2002; 21: 3704-3714
33. Fricker N, Beaudouin J, Richter P, Eils R, Krammer PH, Lavrik IN. Model-based dissection of CD95 signaling dynamics reveals both a pro-And antiapoptotic role of c-FLIPL. J Cell Biol 2010; 190: 377-389
34. Meinander A, Soderstrom TS, Kaunisto A, Poukkula M, Sistonen L, Eriksson JE. Fever-like hyperthermia controls T Lymphocyte persistence by inducing degradation of cellular FLIPshort. J Immunol 2007; 178: 3944-3953
35. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 2001; 21: 5299-5305
36. Bartke T, Siegmund D, Peters N, Reichwein M, Henkler F, Scheurich P et al. p53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-Independent cell death in DLD-1 cells. Oncogene 2001; 20: 571-580
37. Chen S, Cao W, Yue P, Hao C, Khuri FR, Sun SY. Celecoxib promotes c-FLIP degradation through Akt-Independent inhibition of GSK3. Cancer Res 2011; 71: 6270-6281
38. Lin Y, Liu X, Yue P, Benbrook DM, Berlin KD, Khuri FR et al. Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-Induced apoptosis and enhancement of TRAIL-Initiated apoptosis in lung cancer cells. Mol Cancer Ther 2008; 7: 3556-3565
39. Fukazawa T, Fujiwara T, Uno F, Teraishi F, Kadowaki Y, Itoshima T et al. Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells. Oncogene 2001; 20: 5225-5231
40. Hoeller D, Hecker CM, Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer 2006; 6: 776-788
41. Hochstrasser M. Origin and function of ubiquitin-like proteins. Nature 2009; 458: 422-429
42. Staub O, Rotin D. Role of ubiquitylation in cellular membrane transport. Physiol Rev 2006; 86: 669-707
43. Kaunisto A, Kochin V, Asaoka T, Mikhailov A, Poukkula M, Meinander A et al. PKCmediated phosphorylation regulates c-FLIP ubiquitylation and stability. Cell Death Differ 2009; 16: 1215-1226
44. Poukkula M, Kaunisto A, Hietakangas V, Denessiouk K, Katajamaki T, Johnson MS et al. Rapid turnover of c-FLIPshort is determined by its unique C-Terminal tail. J Biol Chem 2005; 280: 27345-27355
45. Odoux C, Fohrer H, Hoppo T, Guzik L, Stolz DB, Lewis DW et al. A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res 2008; 68: 6932-6941